Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 Years and Above.
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Dec 2009 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 27 Oct 2009 Interim results reported in GlaxoSmithKline media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History